Navigation Links
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures

NATICK, Mass., and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed results from the SPIRIT III Clinical Trial, which continue to support the proven safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and add to the growing body of strong clinical evidence for the XIENCE(TM) V (PROMUS(TM)) Everolimus Eluting Coronary Stent System. An analysis of the data was presented by Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and the Principal Investigator of the SPIRIT III Trial, during a late- breaking trial session at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease treated with either the XIENCE V (PROMUS) Stent or the TAXUS Express Stent. Ischemia-driven target lesion revascularization (TLR) for 669 patients treated with the XIENCE V (PROMUS) Stent changed from 2.6% to 3.3% between nine months and one year, while for the 333 patients treated with the TAXUS Stent, TLR changed from 5.0% to 5.6% during the same time period, still failing to reach statistical significance (p=0.09). Target vessel revascularization (TVR) at one year was also similar, with 6.1% for PROMUS and 7.5% for TAXUS (p=0.41).

The overall MACE (Major Adverse Cardiac Events) rate (defined as cardiac death, myocardial infarction (heart attack, or MI) or ischemia-driven TLR) through one year was 5.8% for the XIENCE V (PROMUS) Stent and 9.9% for the TAXUS Stent (p=0.01), reflecting an increased number of small (non-Q wave) MIs at the time of the procedure (2.5% vs. 3.8%).

Subset analysis showed especially strong performance of the TAXUS Stent in diabetic patients with MACE rates remaining low at 4.7%, while MACE rates increased in the XIENCE V (PROMUS) Stent to 8.8%. In long lesions (lesion length>13.2 mm), MACE was 7.7% for the XIENCE V (PROMUS) Stent and 8.0% for the TAXUS Stent; in small vessels (RVD< / =2.775 mm), 6.1% for the XIENCE V (PROMUS) Stent and 12.1% for the TAXUS Stent*.

Stent thrombosis rates through one year were also low for both the TAXUS Stent (0.6%, 0.6%) and the XIENCE V (PROMUS) Stent (0.8%, 1.1%), using protocol and ARC definitions, respectively.

"The SPIRIT III one-year data reaffirms the proven long-term outcomes of the TAXUS Stent," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "We look forward to launching the PROMUS Stent in the U.S., which will complement our paclitaxel-eluting TAXUS Stent by offering physicians a deliverable Olimus option."

The PROMUS Stent has CE Mark approval and is distributed in most European countries and other international markets. The PROMUS Stent is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008. The safety and efficacy of the TAXUS Express2 Stent System have not been established in patients with diabetes, long lesions and small vessels.

SPIRIT is sponsored by Abbott. TAXUS, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

*Subsets were not designed for statistical comparisons and demonstrated the above observational results.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

617-459-2703 (mobile)

Investor Relations

Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Inspire Announces Presentations at Two European Scientific Conferences
Post Your Comments:
(Date:11/30/2015)... Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ... Breast Care to increase collaboration with sub-specialists around the ... --> Sectra (STO: SECT B) ... into a multi-year agreement to provide Breast Imaging PACS ...
(Date:11/29/2015)... and NUREMBERG, Germany , ... meeting, innovation leader Ziehm Imaging invites attendees to experience ... on the market. The highlight on display is Ziehm ... flat-panel technology that provides a 16 cm edge length ... Vision RFD Hybrid Edition, the first fully motorized mobile ...
(Date:11/29/2015)... CHICAGO , Nov. 29, 2015   National ... expansion of its client base, including notable statewide ... the company,s flagship solution, ACR Select, more than ... EHR order entry workflow. ACR Select provides real-time ... a patient,s condition and has been implemented at ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... An inventor from Charlottesville, Va., is concerned about the need ... high blood pressure due to loud noises," she said, "so I decided that there ... as well as radio waves and microwaves." , The baby BABY MUFF prevents loud ...
(Date:11/30/2015)... , ... November 30, 2015 , ... In an interview ... role as a top ophthalmologist on Long Island’s east end. During the broadcast, entitled ... in surgery and treatment of glaucoma and cataracts, and how a visit with his ...
(Date:11/30/2015)... ... 2015 , ... Since its inception, Seniors Guide has been ... living and all other retirement options. Support for issues surrounding the senior community ... top priority. , So it’s no surprise that every November, Seniors Guide ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Kreithen”), one of the leading plastic surgery practices in Florida, is proud to ... to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today ... Meeting. Their Ecosystem empowers dentists to make complex business decisions by providing the tools ... receive a free fee survey with 10 procedures customized by zip code. , ...
Breaking Medicine News(10 mins):